Company
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 5 of 8
The clinical study included the use of a driving simulator, which assesses whether a drug may cause somnolence or impair cognition, and its results will be used to support safety data from future trials for submission to regulatory agencies
The new facility provides MGC Pharma with access to significant capital to fund the execution of its business commercialisation strategy, primarily with Sciensus Rare in the UK and EU and AMC in the USA.
This financing facility provides the company with access to significant capital in order to execute its business commercialisation strategy.
The company believes the integration of this learning AI algorithm could be revolutionary in the health sector, positioning the ZAM app far ahead of market peers.
Getting pharmaceutical products through the regulatory approval process takes time, particularly when the products are phytocannabinoids"
Robert Clements, an expert in market development for rare and chronic diseases, has been appointed to the new role to help drive forward the company’s strategy and goal of becoming a leading supplier of plant-derived medicines.
The data read-out showed ArtemiC Support had a statistically significant impact on shortness of breath, cough, lack of energy, headache and mental confusion
Results have so far indicated CimetrA could be used to treat a wide spectrum of inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), influenza, and dermatological diseases, among others.
The app will “will serve as an 'online doctor', both collecting data and learning from it to predict conflicts in treatments, increasing efficiency for medical practitioners”, said MGC co-founder Roby Zomer
Researchers found CimetrA effectively blocked a key mechanism in inflammatory diseases such as arthritis and asthma
Results indicate that CimetrA may have a wider-ranging application beyond the treatment of the symptoms of COVID-19, which has been the primary focus of clinical trials to date.
"We are excited to start the trials in collaboration with USF at the earliest opportunity this year, particularly with COVID-19 spikes and new variants emerging every few months," said CEO Roby Zomer
The three year-study will be followed by additional research
“This important finding indicates not only improvement in the health status of the patients, but also the improved quality of life of the families and caregivers that are taking care of dementia patients,” MGC said
The article assessing the output from a study of 50 people with the virus was carried in the Journal of Cellular and Molecular Medicine
“We are very pleased that the patent for our proprietary drug delivery system has now been granted by the Slovenian Intellectual Property Office,” said MGC’s managing director and co-founder, Roby Zomer
HempStreet will distribute CimetrA and CannEpil, MGC’s cannabis-based formulations for treating Covid-19, in India
Post the period, MGC pharma signed a new distribution agreement with Netherlands-based Sciensus Rare
The product has potential efficacy in relation to the regulation of the human body's circadian rhythm and homeostasis, which promotes an immune response to bacterial, viral, fungal and parasitic infections.
Its lead asset CimetrA is a plant-based drug containing curcumin and Boswellia and has been developed to treat acute and chronic inflammation caused by flu and viral diseases such as Covid
